Do Antibiotics Impair Efficacy of Immunotherapy in Kidney Cancer?

Article

Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis.

Antibiotics administered less than a month before initiation of programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) immune checkpoint blockade therapy with or without cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitors for patients with advanced kidney cancer might impair tumor control, according to authors of a retrospective analysis that will be presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida (abstract 462).

“Recent use of antibiotics prior to immune checkpoint inhibitor therapy negatively influences outcomes even after adjustment for prognostic risk factors,” noted lead study author Lisa Derosa, MD, of the Gustave Roussy Cancer Institute, Paris-Sud University in Villejuif, France. “These early findings show that doctors prescribing cancer immunotherapy should pay closer attention to antibiotic use.”

The findings might be due to specific gut microbiota. Prior research had suggested that in mice, gut bacteria can interact with immune system cells in a manner that can improve immune checkpoint inhibition’s antitumor efficacy.

The new analysis included 80 patients diagnosed with metastatic renal cell carcinoma (mRCC) who had participated in prospective clinical trials of PD-1 or PD-L1 inhibitors or combination treatments of PD-1 and CTLA-4 inhibitors or PD-L1 inhibition plus bevacizumab. Most patients (88%) had clear-cell mRCC histology. Of the 80 patients, 16 (20%) had been administered broad-spectrum antibiotic agents up to a month prior to initiation of cancer immunotherapy.

Tumors progressed more rapidly among patients who had been administered antibiotics than in those who had not. Objective response rate (ORR) was lower among patients who had received antibiotics (P < .002).

Median progression-free survival was 2.3 months and 8.1 months for the two groups (P < .001). That statistical association survived multivariate adjustments for patient age, gender, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk category, tumor burden, and proton-pump inhibitor status. There was a trend toward a similarly negative association between antibiotics use and overall survival among patients receiving immune checkpoint blockade therapy but it was too soon for any definitive conclusion about that outcome, Derosa cautioned.

The study authors are now investigating the biological mechanisms underlying the association but noted that further studies are needed to better understand how alteration of gut microbiota affects immunotherapy outcomes. It is not yet clear whether the findings have implications for other cancer types but antibiotics are frequently administered to patients with cancer as prophylaxis against infection, Derosa noted.

“As cancer immunotherapy options grow and evolve, we’re beginning to understand more about the relationship between gut bacteria and the immune response to cancer,” noted ASCO Expert Sumanta Pal, MD, of City of Hope in Duarte, California. “It’s remarkable that antibiotic use could have such a negative impact on the efficacy of immunotherapy. This study suggests that patient antibiotic use should be considered carefully so that the possible benefits of immunotherapy are not compromised.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content